Capivasertib Cost-Effectiveness in Advanced Bre...

By Rene Pretorius

April 18, 2025

Capivasertib, a novel AKT inhibitor, has gained approval as a second-line therapy for advanced breast cancer, but its high cost has sparked concerns about ...
Toripalimab Evidence Journey in Cancer Care
Cancer Control Month 2025: Key Takeaways from President Trump’s National Call...
Neoadjuvant Chemoimmunotherapy HNSCC in Advanced HPV-Negative Patients
Prior Authorization Elimination: Is Optum Rx moving towards Access Efficiency?
Pharmaceutical Innovation and Market Access: Insights from Fast Company’s 202...
Enhancing Colorectal Cancer Screening Through Mail and Navigation Strategies
Journavx Market Access Strategy in Focus: What Early Payer Decisions Signal f...
NovoCare and the Rise of Direct-to-Consumer Pharmaceutical Access
AI Moral Decision-Making: Navigating the Complexities of Kidney Allocation De...
Zircaix: A Potential Breakthrough in Kidney Cancer Diagnosis
Personalized Cancer Vaccine in High-Risk Kidney Cancer Patients
ACS Management Innovations: Transforming Patient Outcomes in Acute Coronary S...